Angerona Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -24.01%
- Profit Growth 134.95%
- Ebitda 137.37%
- Net Worth 0.94%
- Total Assets 4.45%
About Angerona Lifesciences
Angerona Lifesciences Private Limited (ALPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 September 2016 (Eight years and five months 12 days old ). Its registered office is in Agra, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Inder Singh and Rupinder Kaur serve as directors at the Company.
Company Details
-
Location
Agra, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909UP2016PTC086080
-
Company No.
086080
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Sep 2016
-
Date of AGM
19 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Angerona Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Inder Singh
|
Additional Director | 09-Oct-2024 | Current |
|
Rupinder Kaur
|
Director | 01-Sep-2016 | Current |
Financial Performance of Angerona Lifesciences.
Angerona Lifesciences Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 24.01% decrease. The company also saw a substantial improvement in profitability, with a 134.95% increase in profit. The company's net worth moved up by a moderate rise of 0.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Angerona Lifesciences?
In 2021, Angerona Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
H.B. Lifecare Private LimitedInder Singh and Rupinder Kaur are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Angerona Lifesciences?
Unlock and access historical data on people associated with Angerona Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Angerona Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Angerona Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
